[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100282072":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":37,"responsibleParty":55,"collaborators":57,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":31,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":31,"enrollmentInfo":73,"targetDuration":31,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":40,"whyStopped":31,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Hospital de Clinicas de Porto Alegre","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IR-MPH","EXPERIMENTAL","Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control",[13],"Drug: Immediate-release Methylphenidate",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Immediate-release Methylphenidate","Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects",[9],[21],"Ritaline",[23],{"name":24,"affiliation":25,"role":26},"Eugênio H Grevet, MD, PhD","Hospital de Clínicas de Porto Alegre","PRINCIPAL_INVESTIGATOR",[28,33],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","+55 51 3359-8094",null,"ehgrevet@gmail.com",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":36},"Claiton HD Bau, MD, PhD","+55 51 33086718","claiton.bau@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Program on Attention-Deficit\u002FHyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre","RECRUITING","Porto Alegre","Rio Grande do Sul","90035-903","Brazil","BR",{"type":47,"coordinates":48},"Point",[49,50],-51.23019,-30.03283,{"lat":50,"lon":49},[53,54],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},{"name":34,"role":29,"phone":35,"phoneExt":31,"email":36},{"type":56,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[58,60,63],{"name":59,"class":6},"Federal University of Rio Grande do Sul",{"name":61,"class":62},"Conselho Nacional de Desenvolvimento Científico e Tecnológico","OTHER_GOV",{"name":64,"class":6},"Coordination for the Improvement of Higher Education Personnel","100282072","phase-4-methylphenidate-in-adults-with-attention-deficithyperactivity-disorder-100282072",false,"NCT02951754","Methylphenidate in Adults With Attention Deficit\u002FHyperactivity Disorder","Inclusion Criteria:\n\n* White Brazilian of European descent\n* Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD\n* Eligibility to immediate-release MPH (IR-MPH) treatment\n\nExclusion Criteria:\n\n* Contraindication for IR-MPH use\n* Current stimulant treatment\n* Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)\n* Current or past history of psychosis\n* Estimated intelligence quotient score lower than 70","ALL","18 Years",{"count":74,"type":75},600,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit\u002FHyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.",[81],"Attention Deficit Disorder With Hyperactivity",[83,84,85,86],"ADHD","Adults","treatment","Methylphenidate","2016-10-31",{"date":89,"type":75},"2016-11-01",{"date":91,"type":31},"2002-02",{"date":93,"type":75},"2032-12",{"name":5,"class":6},1]